Draft:Xufeng Huang

  • Comment: That Distinguished Professorship, if it can be reliably verified, would seem to satisfy WP:NACADEMIC #5. DoubleGrazing (talk) 07:58, 3 October 2024 (UTC)
  • Comment: Entire sections completely unreferenced.
    Please do not cite Amazon as a source. It is a retailer. As such, it is at best a portal to possible sources, not a source in itself. DoubleGrazing (talk) 07:57, 3 October 2024 (UTC)
  • Comment: All the sources are either not independent or do not provide significant coverage of the subject. Please see WP:GNG for the quality of sources required to establish notability. I have found these online that may be of use [1][2]. — GMH Melbourne (talk) 23:27, 25 September 2024 (UTC)

Xufeng Huang
BornBeijing, China
CitizenshipAustralian
Alma materXuzhou Medical University (MBBS)

University of New South Wales (PhD)

University of Wollongong (DSC)
AwardsAustralia National Health and Medical Research Council Principal Research Fellow 2019
Scientific career
FieldsNeuroscience, Obesity, Schizophrenia, Brain Nutrients
Websitehttps://scholars.uow.edu.au/xu-feng-huang

Xu-Feng Huang MD, PhD, DSc is a Distinguished Professor at the University of Wollongong and Principal Research Fellow with the National Health and Medical Research Council (NHMRC), Australia. His career spans both teaching and research at the tertiary institutions. He specializes in the study of brain structure,[1] molecular mechanism of antipsychotic drug action,[2] neuropathology of schizophrenia,[3] and nutrients for brain health.[4]

  1. ^ Paxinos, George; Huang, Xu-Feng; Toga, Arthur (2000-01-01). "The Rhesus Monkey Brain in Stereotaxic Coordinates". Faculty of Health and Behavioural Sciences - Papers (Archive).
  2. ^ Huang, X.‐F.; Weston‐Green, K.; Yu, Y. "Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity". Obesity Reviews. 19 (3): 396–405. doi:10.1111/obr.12638.
  3. ^ Huang, Xu‐Feng; Song, Xueqin. "Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment". Medicinal Research Reviews. 39 (1): 386–403. doi:10.1002/med.21512.
  4. ^ Ge, Xing; Zheng, Mingxuan; Hu, Minmin; Fang, Xiaoli; Geng, Deqin; Liu, Sha; Wang, Li; Zhang, Jun; Guan, Li; Zheng, Peng; Xie, Yuanyi; Pan, Wei; Zhou, Menglu; Zhou, Limian; Tang, Renxian (2023-02-15). "Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models". The Journal of Clinical Investigation. 133 (4). doi:10.1172/JCI154612. PMC 9927952.